缬沙坦 氨氯地平联合治疗原发性高血压的临床有效性和安全性

Clinical Efficacy and Safety of Valsartan and Amlodipine in the Treatment of Essential Hypertension

目的分析评价缬沙坦、氨氯地平联合治疗原发性高血压患者临床有效性及安全性。方法选取2016年1月—2018年1月治疗的102例原发性高血压患者,根据治疗方案不同对照组51例,给予氨氯地平治疗;观察组51例,给予缬沙坦、氨氯地平联合治疗。结果治疗后,两组患者血压水平均显著改善(P<0.05);且组间对比,观察组患者改善幅度更大(P<0.05);观察组患者治疗总有效率为96.08%,对照组为70.59%,有显著性差异(P<0.05);两组患者不良反应发生率无明显差异(5.88%vs 7.84%,P>0.05)。结论对原发性高血压患者采取缬沙坦、氨氯地平联合治疗,临床疗效可靠,安全性高,具有推广价值。

Objective To investigate the clinical efficacy and safety of valsartan and amlodipine in patients with essential hypertension. Methods One hundred and two patients with essential hypertension treated in our hospital between January 2016 and January 2018 were enrolled in this experiment, who were randomly divided into the observation group and control group, with 51 cases in each. The control group was administrated with amlo- dipine orally, while the observation group was given valsartan and amlodipine.Results Blood pressure decreased singnificantly in both groups, especially in the observation group（P〈0.05）.The total effective rate was 96.08% in the observation group and 70.59% in the control group. There was no significant difference in the incidence of adverse reactions between the two groups（5.88%vs7.84%,P〉0.05）.Conclusion The combination of valsartan and amlodipine is effective and safe for patients with essential hypertension.